Bayer Ag Stock Performance
| BAYZF Stock | USD 20.15 0.26 1.31% |
The firm shows a Beta (market volatility) of -0.13, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Bayer AG are expected to decrease at a much lower rate. During the bear market, Bayer AG is likely to outperform the market. At this point, Bayer AG has a negative expected return of -0.62%. Please make sure to confirm Bayer AG's value at risk, daily balance of power, as well as the relationship between the Daily Balance Of Power and price action indicator , to decide if Bayer AG performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bayer AG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 4.2 B | |
| Total Cashflows From Investing Activities | 855 M |
Bayer |
Bayer AG Relative Risk vs. Return Landscape
If you would invest 3,089 in Bayer AG on August 30, 2024 and sell it today you would lose (1,074) from holding Bayer AG or give up 34.77% of portfolio value over 90 days. Bayer AG is currently producing negative expected returns and takes up 2.8459% volatility of returns over 90 trading days. Put another way, 25% of traded pink sheets are less volatile than Bayer, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Bayer AG Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bayer AG's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bayer AG, and traders can use it to determine the average amount a Bayer AG's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2192
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BAYZF |
Estimated Market Risk
| 2.85 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.62 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.22 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bayer AG is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bayer AG by adding Bayer AG to a well-diversified portfolio.
Bayer AG Fundamentals Growth
Bayer Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bayer AG, and Bayer AG fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bayer Pink Sheet performance.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0576 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.41 B | |||
| Shares Outstanding | 982.42 M | |||
| Price To Earning | 321.83 X | |||
| Price To Book | 1.36 X | |||
| Price To Sales | 1.06 X | |||
| Revenue | 44.08 B | |||
| EBITDA | 6.45 B | |||
| Cash And Equivalents | 8.19 B | |||
| Cash Per Share | 8.34 X | |||
| Total Debt | 35.55 B | |||
| Debt To Equity | 1.17 % | |||
| Book Value Per Share | 42.01 X | |||
| Cash Flow From Operations | 5.09 B | |||
| Earnings Per Share | 5.13 X | |||
| Total Asset | 120.24 B | |||
| Current Asset | 25.17 B | |||
| Current Liabilities | 16.68 B | |||
About Bayer AG Performance
By analyzing Bayer AG's fundamental ratios, stakeholders can gain valuable insights into Bayer AG's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bayer AG has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bayer AG has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Bayer Ag is traded on OTC Exchange in the United States.Things to note about Bayer AG performance evaluation
Checking the ongoing alerts about Bayer AG for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bayer AG help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bayer AG generated a negative expected return over the last 90 days |
- Analyzing Bayer AG's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bayer AG's stock is overvalued or undervalued compared to its peers.
- Examining Bayer AG's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bayer AG's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bayer AG's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bayer AG's pink sheet. These opinions can provide insight into Bayer AG's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bayer Pink Sheet analysis
When running Bayer AG's price analysis, check to measure Bayer AG's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bayer AG is operating at the current time. Most of Bayer AG's value examination focuses on studying past and present price action to predict the probability of Bayer AG's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bayer AG's price. Additionally, you may evaluate how the addition of Bayer AG to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |